文献速递胸部肿瘤

建立可重现EML4-ALK阳性人非小细胞肺癌的条件转基因小鼠模型

Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2016-11-09

研究利用C57BL/6N小鼠建立携带LoxP-STOP-LoxP-FLAGS标签人EML4-ALK(变异1)转基因的条件转基因小鼠品系,与SPC-Cre-雌激素受体融合蛋白小鼠杂交,他莫昔芬诱导后1周肺部出现肿瘤,克唑替尼治疗2周肿瘤明显缩小且无毒性征象,延长治疗出现获得性耐药及ALK G1202R突变。

要点

  • 他莫昔芬诱导后1周即发生肺部EML4-ALK肿瘤,肺内强表达而其他器官不表达。
  • 克唑替尼治疗2周诱导肿瘤明显缩小,无毒性征象。
  • 延长克唑替尼治疗出现获得性耐药,耐药结节携带ALK G1202R突变。

核心结论

  • 成功建立了肿瘤发生时间短的EML4-ALK转基因小鼠耐药研究模型,作者认为该模型应成为测试ALK酪氨酸激酶抑制剂疗效的强有力临床前模型,为研究获得性耐药机制和探索ALK阳性肺癌新治疗策略提供有用工具。

研究设计与样本

  • 研究使用C57BL/6N小鼠建立携带LoxP-STOP-LoxP-FLAGS标签人EML4-ALK(变异1)转基因的条件转基因小鼠品系。
  • 将EML4-ALK转基因小鼠与在表面活性蛋白C基因(SPC)控制下表达Cre-雌激素受体融合蛋白的小鼠杂交,建立肺特异性可诱导表达EML4-ALK融合蛋白的转基因小鼠模型。
  • 通过腹腔注射他莫昔芬诱导EML4-ALK转基因表达。

主要发现

  • 他莫昔芬治疗1周后发生EML4-ALK肿瘤。
  • EML4-ALK在肺内强表达,其他器官不表达;免疫组化观察到ALK和FLAGS表达。
  • 对携带EML4-ALK肿瘤的小鼠给予克唑替尼治疗2周,诱导肿瘤明显缩小,无毒性征象。
  • 延长克唑替尼治疗导致肿瘤获得性耐药,出现再生长和疾病进展。
  • 耐药肿瘤结节显示获得性ALK G1202R突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion is a distinct molecular subclassification of NSCLC that is targeted by anaplastic lymphoma kinase (ALK) inhibitors. We established a transgenic mouse model that expresses tumors highly resembling human NSCLC harboring echinoderm microtubule associated protein like 4 gene (EML)-ALK fusion. We aimed to test an EML4-ALK transgenic mouse model as a platform for assessing the efficacy of ALK inhibitors and examining mechanisms of acquired resistance to ALK inhibitors. METHODS: Transgenic mouse lines harboring LoxP-STOP-LoxP-FLAGS-tagged human EML4-ALK (variant 1) transgene was established by using C57BL/6N mice. The transgenic mouse model with highly lung-specific, inducible expression of echinoderm microtubule associated protein like 4-ALK fusion protein was established by crossing the EML4-ALK transgenic mice with mice expressing Cre-estrogen receptor fusion protein under the control of surfactant protein C gene (SPC). Expression of EML4-ALK transgene was induced by intraperitoneally injecting mice with tamoxifen. When the lung tumor of the mice treated with the ALK inhibitor crizotinib for 2 weeks was measured, tumor shrinkage was observed. RESULTS: EML4-ALK tumor developed after 1 week of tamoxifen treatment. Echinoderm microtubule associated protein like 4-ALK was strongly expressed in the lung but not in other organs. ALK and FLAGS expressions were observed by immunohistochemistry. Treatment of EML4-ALK tumor-bearing mice with crizotinib for 2 weeks induced dramatic shrinkage of tumors with no signs of toxicity. Furthermore, prolonged treatment with crizotinib led to acquired resistance in tumors, resulting in regrowth and disease progression. The resistant tumor nodules revealed acquired ALK G1202R mutations. CONCLUSIONS: An EML4-ALK transgenic mouse model for study of drug resistance was successfully established with short duration of tumorigenesis. This model should be a strong preclinical model for testing efficacy of ALK TKIs, providing a useful tool for investigating the mechanisms of acquired resistance and pursuing novel treatment strategies in ALK-positive lung cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Pyo KH, Lim SM, Kim HR, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2016. PMID: 27836576. doi:10.1016/j.jtho.2016.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。